c-MYC partners with BPTF in human cancer
- 3 May 2016
- journal article
- opinion
- Published by Taylor & Francis in Molecular & Cellular Oncology
- Vol. 3 (3) , e1152346
Abstract
The c-MYC oncogene is deregulated in virtually all human tumors and therefore constitutes an attractive therapeutic target. We found that the chromatin remodeler BPTF is a c-MYC interactor required for c-MYC chromatin recruitment and transcriptional activity. Moreover, inhibition of BPTF delays tumor development both in vitro and in vivo and its levels positively correlate with c-MYC signatures in human tumors. We propose BPTF as a therapeutic target in c-MYC-addicted tumors.Keywords
This publication has 10 references indexed in Scilit:
- Interaction with WDR5 Promotes Target Gene Recognition and Tumorigenesis by MYCMolecular Cell, 2015
- Genome Recognition by MYCCold Spring Harbor Perspectives in Medicine, 2014
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaNature, 2011
- The Nucleosome Remodeling FactorFEBS Letters, 2011
- Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblastsOncogene, 2011
- Apoptotic signaling by c-MYCOncogene, 2008
- Modelling Myc inhibition as a cancer therapyNature, 2008
- Myc-binding-site recognition in the human genome is determined by chromatin contextNature Cell Biology, 2006
- Transcriptional regulation and transformation by Myc proteinsNature Reviews Molecular Cell Biology, 2005
- Binding of myc proteins to canonical and noncanonical DNA sequences.Molecular and Cellular Biology, 1993